【国会预算办公室】增加镰状细胞病基因治疗的使用将如何影响联邦预算-2024.12_13页_432kb

Summary of "How Increased Use of Gene Therapy Treatment for Sickle Cell Disease Could Affect the Federal Budget"

Core Content

This report by the Congressional Budget Office (CBO) evaluates the potential budgetary impacts of increasing the use of gene therapy for the treatment of sickle cell disease (SCD) in the United States. SCD is a common inherited blood disorder, primarily affecting non-Hispanic Black or African American populations, and leads to significant health and economic burdens due to its high treatment costs and reduced life expectancy.

Main Points

Overview of Gene Therapy

• Gene therapies replace or modify disease-causing genes to prevent, cure, or treat diseases.
• They are particularly suitable for inherited diseases like SCD, which result from a single gene mutation.
• Unlike traditional treatments, gene therapies can address the root cause of the disease, potentially offering a one-time cure.

Sickle Cell Disease (SCD)

• Affects approximately 100,000 people in the U.S., with over 90% being non-Hispanic Black or African American.
• Causes red blood cells to become sickle-shaped, leading to pain crises, organ damage, and reduced life expectancy by about 20 years.
• Current standard of care includes symptom management and treatment of pain crises, with no cure available for most patients.

Approved Gene Therapies for SCD

• Lyfgenia and Casgevy are the first FDA-approved gene therapies for SCD.
• Both therapies involve a complex, multi-step process including stem cell collection, modification, and reinfusion.
• Each therapy has a list price exceeding $2 million, but Medicaid rebates reduce the net cost.
• Clinical trials show promising results, with most patients experiencing resolution of pain crises.

Insurance Coverage and Costs

• SCD patients are predominantly covered by Medicaid and Medicare.
• Medicaid covers gene therapies for SCD but may impose utilization controls.
• Medicare has approved add-on payments for these therapies, up to $2.325 million for Lyfgenia and $1.65 million for Casgevy in fiscal year 2025.
• Commercial insurance coverage is more restrictive, with conditions such as prior pain crisis history and failed medication trials.

Policy Approaches to Increase Use

• Policymakers could expand access by modifying coverage and payment policies.
• Increasing the federal role in Medicaid could reduce state-level utilization controls.
• Value-based payment models could be introduced to align payments with treatment outcomes.
• Medicare could also adjust payment policies, such as increasing add-on payments or using bundled payments, to encourage broader adoption.

Key Information

Treatment Costs and Outcomes

• Gene therapies are expensive, but they may reduce long-term health care costs by curing the disease.
• Long-term outcomes and safety data are still being collected, but early evidence suggests reduced future health care use.

Budgetary Effects Categories

• Changes in treatment costs: Dependent on the number of patients and cost differences compared to current law.
• Conventional effects: Savings from improved health and lower disability rates.
• Population-change effects: Increased longevity may lead to higher benefit costs and more tax revenue.
• Dynamic effects: Consider broader economic impacts, such as changes in GDP and employment, though typically not significant for individual therapies.

CBO's Methodology

• CBO would estimate the number of SCD patients who would receive gene therapy under a policy.
• It would analyze the effects on federal outlays and revenues, including direct treatment costs, hospitalization expenses, and potential long-term savings.
• The agency would also consider the economic implications of increased longevity and changes in health care utilization.

Conclusion

The increased use of gene therapies for SCD could significantly reduce future health care costs but may initially increase federal spending due to the high upfront treatment costs. CBO's analysis would take into account various factors, including insurance coverage, treatment complexity, and long-term health outcomes, to provide a comprehensive estimate of the budgetary effects. The potential for value-based payment models and policy reforms to influence both access and cost is a central theme of the report.